86 related articles for article (PubMed ID: 23323567)
1. Dosing time-dependent effect of raloxifene on plasma plasminogen activator inhibitor-1 concentrations in post-menopausal women with osteoporosis.
Ando H; Otoda T; Ookami H; Nagai Y; Inano A; Takamura T; Ushijima K; Hosohata K; Matsushita E; Saito T; Kaneko S; Fujimura A
Clin Exp Pharmacol Physiol; 2013 Mar; 40(3):227-32. PubMed ID: 23323567
[TBL] [Abstract][Full Text] [Related]
2. The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.
Ozeren M; Karahan SC; Ozgur M; Eminagaoglu S; Unsal M; Baytan S; Bozkaya H
Acta Obstet Gynecol Scand; 2005 Oct; 84(10):987-91. PubMed ID: 16167916
[TBL] [Abstract][Full Text] [Related]
3. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
[TBL] [Abstract][Full Text] [Related]
4. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.
Dias AR; Melo RN; Gebara OC; D'Amico EA; Nussbacher A; Halbe HW; Pinotti JA
Climacteric; 2005 Mar; 8(1):63-70. PubMed ID: 15804733
[TBL] [Abstract][Full Text] [Related]
5. The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities.
Hansdóttir H; Franzson L; Prestwood K; Sigurdsson G
J Am Geriatr Soc; 2004 May; 52(5):779-83. PubMed ID: 15086661
[TBL] [Abstract][Full Text] [Related]
6. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
7. Procoagulant state after raloxifene therapy in postmenopausal women.
Azevedo GD; Franco RF; Baggio MS; Maranhão TM; Sá MF
Fertil Steril; 2005 Dec; 84(6):1680-4. PubMed ID: 16359964
[TBL] [Abstract][Full Text] [Related]
8. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature.
Cosman F; Baz-Hecht M; Cushman M; Vardy MD; Cruz JD; Nieves JW; Zion M; Lindsay R
Thromb Res; 2005; 116(1):1-13. PubMed ID: 15850603
[TBL] [Abstract][Full Text] [Related]
9. Safety assessment of raloxifene over eight years in a clinical trial setting.
Martino S; Disch D; Dowsett SA; Keech CA; Mershon JL
Curr Med Res Opin; 2005 Sep; 21(9):1441-52. PubMed ID: 16197663
[TBL] [Abstract][Full Text] [Related]
10. Effect of raloxifene and clodronate on bone density in postmenopausal osteoporotic women.
D'Amelio P; Muratore M; Tinelli F; Tamone C; Cosentino L; Quarta E; Calcagnile F; Carlo Isaia G
Int J Tissue React; 2003; 25(2):73-8. PubMed ID: 14518596
[TBL] [Abstract][Full Text] [Related]
11. [Effects of raloxifene combined with conjugated equine estrogen on prothrombotic state in ovariectomized rats].
Gao H; Xi S; Xu L
Zhonghua Fu Chan Ke Za Zhi; 2013 Dec; 48(12):935-8. PubMed ID: 24495689
[TBL] [Abstract][Full Text] [Related]
12. The hemorheological effects of raloxifene in postmenopausal women with osteoporosis. Results of a 3-year placebo-controlled clinical trial.
Shand B; Gilchrist N; Blackwell T; March R
Clin Hemorheol Microcirc; 2002; 26(4):249-55. PubMed ID: 12122230
[TBL] [Abstract][Full Text] [Related]
13. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system.
Eilertsen AL; Liestøl S; Mowinckel MC; Hemker HC; Sandset PM
Thromb Haemost; 2007 Jun; 97(6):938-43. PubMed ID: 17549295
[TBL] [Abstract][Full Text] [Related]
14. [Raloxifene (Celvista, Evista)].
Body JJ; Sternon J
Rev Med Brux; 2000 Feb; 21(1):35-41. PubMed ID: 10748686
[TBL] [Abstract][Full Text] [Related]
15. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
[TBL] [Abstract][Full Text] [Related]
16. [Effects of SERMs on bone health. The evaluation of raloxifene treatment for elderly women with osteoporosis using bone turnover markers].
Hasegawa M; Ichimura S; Satomi K
Clin Calcium; 2010 Mar; 20(3):413-20. PubMed ID: 20190372
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis.
Eilertsen AL; Sandvik L; Mowinckel MC; Andersen TO; Qvigstad E; Sandset PM
Thromb Res; 2007; 120(3):371-9. PubMed ID: 17156824
[TBL] [Abstract][Full Text] [Related]
18. Effects of raloxifene treatment on the phenotype of blood monocytes.
Boudjeltia KZ; Durez P; Oberweis D; Guillaume M; Remacle C; Cauchie P; Vanhaeverbeek M; Brohée D; Ducobu J; Gregoir C
Can J Physiol Pharmacol; 2010 May; 88(5):601-5. PubMed ID: 20555430
[TBL] [Abstract][Full Text] [Related]
19. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study.
Checa MA; Garrido A; Prat M; Conangla M; Rueda C; Carreras R
Maturitas; 2005 Sep; 52(1):70-7. PubMed ID: 16143228
[TBL] [Abstract][Full Text] [Related]
20. Effects of raloxifene on platelet functions in patients with postmenopausal osteoporosis.
Ertugrul DT; Gürsoy A; Yücel M; Sahin M; Unal AD; Pamuk B; Berberoglu Z; Aytürk S; Tutuncu NB; Demirag NG
Platelets; 2006 Sep; 17(6):351-3. PubMed ID: 16973494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
